iTeos Therapeutics



HBM contact: Dr Priyanka Belawat

Company status: private

iTeos Therapeutics is targeting the tumor microenvironment to enhance the effectiveness of T-cells at eradicating cancer. iTeos has a broad pipeline focused on multiple complementary mechanisms of action including small molecules targeting A2A as well as antibodies directed to TIGIT.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171